# RC48-C005 (NCT03507166)

> A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

No report yet. It can be ordered.

- Drugs tested: disitamab vedotin
- Indication: HER2-positive locally advanced or metastatic urothelial carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03507166
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: RemeGen Co., Ltd.
- Conditions: Urothelial Carcinoma; Advanced Cancer
- Interventions: RC48-ADC
- Enrollment: 43
- Primary outcome: Objective Response Rate （ORR）

## Indexed commentary on RC48-C005 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=rc48-c005-nct03507166